Gene Editing Collaboration and Licensing Deals 2016-2026

Description

The definitive benchmark for gene editing dealmaking

Gene editing partnering is driven by advanced platform technologies and rapid innovation, with deal structures reflecting access to proprietary tools, intellectual property, and next-generation therapeutic capabilities.

This report provides a comprehensive and structured analysis of 410 gene editing collaboration and licensing deals, delivering a clear and evidence-based view of how partnerships are designed, negotiated, and executed across the market.

Establish a clear view of market standards

The report enables a precise understanding of how gene editing deals are structured in practice, allowing you to:

Benchmark comparable transactions with confidence
Detailed analysis of upfronts, milestones, and royalty structures across relevant deals
Define realistic market parameters
Clear insight into how deal terms vary by platform type, application, and partner profile
Support valuation and structuring decisions with evidence
Ground internal discussions in real transaction data rather than assumptions
Understand how leading companies approach dealmaking
Visibility into partner behaviour and recurring deal structures across a highly innovative and IP-driven landscape
Full visibility into deal structure and execution
Beyond headline deal data, the report provides access to underlying contract documents, enabling a detailed understanding of how agreements are constructed in practice.

This includes:

Rights granted and retained
Development and commercialization responsibilities
Financial structures and payment triggers
Key contractual provisions and protections
This level of transparency is critical to understanding how value, risk, and control are allocated within gene editing partnerships, particularly in areas involving platform access, IP positioning, and emerging therapeutic applications.
Designed for real-world BD and strategy use

The report is widely used to:

Structure and benchmark platform and advanced technology transactions
Prepare for negotiations with well-defined market context
Evaluate licensing, co-development, and technology partnerships
Support internal strategy with robust, defensible data
What's included
410 gene editing collaboration and licensing deals
Financial terms, including upfronts, milestones, and royalties where disclosed
Fully searchable deal directory (by company, platform, and application)
Direct access to SEC-filed agreements and source documents
Analysis of deal trends, key transactions, and active dealmakers
A trusted, evidence-based reference for gene editing dealmaking
Combining comprehensive deal coverage with contract-level insight, this report provides a trusted, evidence-based reference for how gene editing partnerships are structured, negotiated, and valued.

Product Code: CP2150

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in gene editing dealmaking

2.1. Introduction
2.2. Gene editing deals over the years
2.3. Most active gene editing dealmakers
2.4. Gene editing deals by deal type
2.5. Gene editing deals by therapy area
2.6. Gene editing deals by industry sector
2.7. Deal terms for gene editing deals
- 2.7.1 Gene editing deals headline values
- 2.7.2 Gene editing deal upfront payments
- 2.7.3 Gene editing deal milestone payments
- 2.7.4 Gene editing royalty rates

Chapter 3 - Leading gene editing deals

3.1. Introduction
3.2. Top gene editing deals by value

Chapter 4 - Most active gene editing dealmakers

4.1. Introduction
4.2. Most active gene editing dealmakers
4.3. Most active gene editing deals company profiles

Chapter 5 - Gene editing contracts dealmaking directory

5.1. Introduction
5.2. Gene editing contracts dealmaking directory

Chapter 6 - Gene editing dealmaking by technology type

Deal directory
Deal directory - Gene editing deals by company A-Z
Deal directory - Gene editing deals by deal type
Deal directory - Gene editing deals by therapy area
Deal type definitions
About Biopharma Research Ltd
Current Partnering
Current Agreements
Recent report titles from Current Partnering

Table of figures

Figure 1: Gene editing deals since 2016
Figure 2: Active gene editing dealmaking activity since 2016
Figure 3: Gene editing deals by deal type since 2016
Figure 4: Gene editing deals by therapy area since 2016
Figure 5: Gene editing deals by industry sector since 2016
Figure 6: Gene editing deals with a headline value
Figure 7: Gene editing deals with an upfront value
Figure 8: Gene editing deals with a milestone value
Figure 9: Gene editing deals with a royalty rate value
Figure 10: Top gene editing deals by value since 2016
Figure 11: Most active gene editing dealmakers since 2016
Figure 12: Gene editing deals by technology type since 2016